Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 2Other hematologic neoplasm 1

Conditions

Prostatic Neoplasms 63Lymphoma, Large B-Cell, Diffuse 47Lymphoma 33Burkitt Lymphoma 27Lymphoma, Follicular 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Lymphoma, Non-Hodgkin 14Neoplasms 13Lymphoma, B-Cell 11Lymphoma, T-Cell, Peripheral 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 9Hodgkin Disease 9Lymphoma, B-Cell, Marginal Zone 8Leukemia 8Recurrence 6Prostatic Neoplasms, Castration-Resistant 6Multiple Myeloma 6Leukemia, Lymphocytic, Chronic, B-Cell 6Neoplasm Metastasis 5Leukemia, Biphenotypic, Acute 5Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoproliferative Disorders 4Lymphoma, T-Cell 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Anaplastic 4Immunoblastic Lymphadenopathy 4Ovarian Neoplasms 3Myasthenia Gravis 3Melanoma 3Lymphoma, AIDS-Related 3

Interventions

Cyclophosphamide 9mogamulizumab 6Biopsy 6fludarabine 5fludarabine phosphate 4Specimen Handling 4Immunoglobulin G 4Disulfides 4Brentuximab Vedotin 4ruxolitinib 3romidepsin 3pembrolizumab 3Peripheral Blood Stem Cell Transplantation 3Mycophenolic Acid 3Magnetic Resonance Spectroscopy 3Lenalidomide 3Etoposide 3Busulfan 3hypericin 2Whole-Body Irradiation 2Vincristine 2Tacrolimus 2Prednisone 2Nivolumab 2Melphalan 2Depsipeptides 2tofacitinib 1thymoglobulin 1tazemetostat 1talimogene laherparepvec 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma, T-Cell, Cutaneous × Prednisone × 1 year × Clear all
NCT07535710 2026-04-17

Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma

Shanghai Jiao Tong University School of Medicine

Phase 1/2 Not yet recruiting
37 enrolled
DermatologicLymphoid

Recurrence, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT05996185 2026-04-14

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

Yale University

Phase 2 Recruiting
22 enrolled
DermatologicLymphoidOther hematologic neoplasm

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡